Seattle Genetics (SGEN) Sets Date with FDA to Review Biologics License Applications for Brentuximab Vedotin
Go back to Seattle Genetics (SGEN) Sets Date with FDA to Review Biologics License Applications for Brentuximab Vedotin| Seattle Genetics Inc /wa (NASDAQ: SGEN) | Delayed: 228.74 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $228.74 | 52 Week High | $75.36 | |||
| Open | $22.94 | 52 Week Low | $26.02 | |||
| Day High | $228.74 | P/E | N/A | |||
| Day Low | $228.74 | EPS | $-0.51 | |||
| Volume | 759,302 | |||||
